would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel, ZRG1 VACC 03: R21 applications: AIDS Vaccines.

Date: July 29, 2003.

Time: 8:30 a.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Select Bethesda, 8120 Wisconsin Ave., Bethesda, MD 20814.

Contact Person: Mary Clare Walker, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 7852, Bethesda, MD 20892, (301) 435–1165.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Salmonella Physiology.

Date: July 29, 2003.

Time: 3 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Melody Mills, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, MSC 7808, Room 3206, Bethesda, MD 20892, 301–435–0903.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Emphasis Panel, ZRG1 VACC 05—AIDS Vaccines.

Date: July 29, 2003.

Time: 4 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Select Bethesda, 8120 Wisconsin Ave., Bethesda, MD 20814.

Contact Person: Mary Clare Walker, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 7852, Bethesda, MD 20892, (301) 435–1165.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel, ZRG1 VACC 01: Vaccines of Infectious Diseases.

Date: July 30–31, 2003.

Time: 8:30 a.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Select Bethesda, 8120 Wisconsin Ave., Bethesda, MD 20814.

Contact Person: Mary Clare Walker, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 7852, Bethesda, MD 20892 (301) 435–1165.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel, ZRG1 VACC 04; Viral Vaccines.

Date: July 31, 2003.

Time: 3 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: 8120 Wisconsin Ave., Bethesda, MD 20814.

Contact Person: Mary Clare Walker, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 7852, Bethesda, MD 20892 (301) 435–1165.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel, ZRG1 VACC 10: Small Business—Infectious Disease Vaccines.

Date: August 1, 2003.

Time: 8:30 a.m. to 5 p.m

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Select Bethesda, 8120 Wisconsin Ave., Bethesda, MD 20814.

Contact Person: Mary Clare Walker, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 7852, Bethesda, MD 20892 (301) 435–1165.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Immunology.

Date: August 19, 2003.

Time: 1 p.m to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Calbert A. Laing, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4210, MSC 7812, Bethesda, MD 20892 (301) 435–1221, *laingc@csr.nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel, Toll Receptors in Innate Immunity.

Date: August 19, 2003.

Time: 1:30 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Tina McIntyre, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4202, MSC 7812, Bethesda, MD 20892 (301) 594–6375, *mcintyrt@csr.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.893, National Institutes of Health, HHS)

Dated: July 22, 2003.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03–19297 Filed 7–29–03; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Instrumentation Systems and Associated Reagents for High Speed Parallel Molecular Nucleic Acid Sequencing for Performing Single Molecule Nucleic Acid Analysis

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in Patent Applications U.S. 60/151,580, filed August 29, 1999, PCT/US00/23736, filed August 29, 2000, and U.S. 10/070,053, filed June 10, 2002, entitled ''High Speed Parallel Molecular Nucleic Acid Sequencing'', to LI-COR, Inc., having a place of business in Lincoln, NE. The patent rights in this invention have been assigned to the United States of America.

DATES: Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before September 29, 2003, will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Cristina Thalhammer-Reyero, Ph.D., M.B.A., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; E-mail: *ThalhamC@mail.nih.gov*; Telephone: 301–435–4507; Facsimile: 301–402–0220.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless, within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. § 209 and 37 CFR § 404.7.

The invention relates to a method and apparatus for DNA sequencing, also known as Two Dye Sequencing (TDS). This invention is based on Fluorescence Resonance Energy Transfer (FRET), a technology increasingly in use for several molecular analysis purposes. In particular, the method consists of: (1) Attachment of engineered DNA polymerases labeled with a donor fluorophore to the surface (chamber) of a microscope field of view, (2) addition to the chamber of DNA with an annealed oligonucleotide primer, which is bound by the polymerase, (3) further addition of four nucleotide triphosphates, each labeled on the base with a different fluorescent acceptor dye, (4) excitation of the donor fluorophore with light of a wavelength specific for the donor but not for any of the acceptors, resulting in the transfer of the energy associated with the excited state of the donor to the acceptor fluorophore for a given nucleotide, which is then radiated via FRET, (5) identification of the nucleotides most recently added to the chamber by recording the fluorescent spectrum of the individual dye molecules at specific locations in the microscope field, and (6) converting the sequential spectrum into a DNA sequence for each DNA molecule in the microscope field of view.

The field of use may be limited to instrumentation systems and associated reagents for performing single molecule nucleic acid analysis.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: July 17, 2003.

Steven M. Ferguson,

Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 03–19296 Filed 7–29–03; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Bureau of Citizenship and Immigration Services

[BCIS No. 2207–02]

Redesign of Form I–327, Permit to Reenter the United States, and Form I–571, Refugee Travel Document

AGENCY: Bureau of Citizenship and Immigration Services, U.S. Department of Homeland Security.

ACTION: Notice.

SUMMARY: This notice announces that during fiscal year 2003 the Bureau of Citizenship and Immigration Services (BCIS) will begin issuing a new single passport-style travel document that, depending on the circumstances, will either contain the Form I–327, Permit to Reenter the United States, or Form I–571, Refugee Travel Document. Development of the redesigned travel document is intended to reduce production time, improve customer service and strengthen the booklet's security features. Enhanced technologies, similar to those used in the production of the United States Passport, will be employed in printing the BCIS travel document to prevent counterfeiting, tampering and other fraudulent schemes. The new document will be produced at the BCIS Nebraska Service Center in Lincoln, NE, where the two separate travel booklets are currently prepared. On March 1, 2003, the Immigration and Naturalization Service (INS) transferred from the Department of Justice to the Department of Homeland Security (DHS), pursuant to the Homeland Security Act of 2002 (Pub. L. 107–296). The INS adjudications functions transferred to the Bureau of Citizenship and Immigration Services of DHS.

DATES: This notice is effective July 30, 2003.

FOR FURTHER INFORMATION CONTACT: Sandra Schatz Landis, Chief, Immigration Card Production Services (ICPS) Branch, Bureau of Citizenship and Immigration Services, 800 K Street, Room 1000, Washington, DC 20536, telephone (202) 305–8010.

SUPPLEMENTARY INFORMATION:

Background

Who Uses the Forms I–327 and I–571?

Form I–327, Permit to Reenter the United States. The Form I–327 allows a lawful permanent or conditional permanent resident of the United States to apply for admission into the United States upon returning from abroad without having to obtain a returning resident visa.

Form I–571, Refugee Travel Document. A refugee travel document is issued pursuant to Article 28 of the United Nations Convention of July 29, 1951, for the purpose of travel. It may be issued to a person who is in the United States as a refugee pursuant to section 207 of the Immigration and Nationality Act (Act), as an asylee pursuant to section 208 of the Act, or as a permanent resident who received such status as a direct result of refugee or asylee status. A lawfully obtained, currently valid Form I–571, shall be accepted in lieu of any travel document which otherwise would be required from such person under the Act.

How Can a Person Apply for Forms I–327 or I–571?

An application for a Form I–327 or Form I–571 must be filed on Form I–131, Application for Travel Document, with the fee as required in 8 CFR 103.7(b)(1) and with the initial evidence required on the application form. The applicant must state the length of intended absence or absences, and the reasons for travel. Except as provided in 8 CFR 223.2(b)(2)(ii), the application may be approved if filed by an eligible person who is within the United States at the time of submission.

Will the fee For Filing Form I–131 Change?

Until the BCIS conducts a new fee study, the current fee of $110 will not change as a result of issuing the single passport-style travel document.

Where Should the Form I–131 Be Filed?

Applicants must file the application according to the instructions on Form I–131 at the Nebraska Service Center.

May an Applicant Request Expedited Processing of the Travel Document in an Emergency?

To deal fairly and equitably with applicants for travel documents, it is BCIS policy that cases be processed in chronological order by date of receipt.

However, an exception may be permitted in emergency situations if the request is approved by the Nebraska Service Center director, deputy director or an official acting in such capacity.

How Does the BCIS Plan To Implement the Production of the New Travel Document?

The document will be produced at the Nebraska Service Center where the separate travel booklets are now prepared.